What Matters Now
CME
Optimizing Comprehensive Molecular Profiling in Advanced NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Anna-Lena Meinhardt, M.D., Ph.D., National Cancer Institute
95% of Peers Changed Their Practice After this Clinical Scenario
CME
Clinicians face uncertainty in deciding between further molecular testing and immediate therapy for HER2-mutant NSCLC progression.
What Matters Now
CME
Optimizing Comprehensive Molecular Profiling in Advanced NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Anna-Lena Meinhardt, M.D., Ph.D., National Cancer Institute
Corresponding Scenario
After Progression on HER2-Targeted Therapy: Choosing What Comes Next
See experiences from 144 peers
Clinicians face uncertainty in deciding between further molecular testing and immediate therapy for HER2-mutant NSCLC progression.
How clinicians responded after this Clinical Scenario
66
%
begin unsure how to apply evidence
95
%
will implement a practice change
NEW!
Sharpen your clinical judgment for real-world care.
Discover how experts and peers reason
See where small differences in reasoning change safety, feasibility, and escalation decisions.
Reflect on your decision logic
Practice the thinking you used and spot gaps in judgment.
Calibrate your clinical reasoning
Side-by-side, reasoning patterns from peer and experts and how others de-risk their decisions.
Preview
Example: How Your Clinical Reasoning Compares with Peers
This table shows a representative example. Your actual peer comparison is generated after scenario completion.
CME Information
Title: Optimizing Comprehensive Molecular Profiling in Advanced NSCLC: A Full Circle Learning Experience to Close the Testing-to-Treatment Gap.
• Jointly provided by Postgraduate Institute for Medicine and StitchedHealth, Inc.
• Release date: March 24, 2026
• Expiration date: March 24, 2027
• Estimated time to complete activity: 15 min to 2 hours hours
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Target Audience
This activity is intended for medical oncology physicians, nurse practitioners, and physician assistants involved in the care of patients with non-small cell lung cancer
Get Started
Ready to refine your clinical judgment for everyday practice?
In a short (10 min) interactive scenario, explore how experts and peers reason through uncertainty and apply evidence in real-world care.
95% practice change rate among peers